Nivolumab Monotherapy in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma

This follow-up of a randomized phase 3 trial compares the 3-year survival with nivolumab vs that with dacarbazine in patients with previously untreated BRAF wild-type advanced melanoma.

https://ift.tt/2PouJZl